A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept®
Sponsor: Corium, Inc.
Listed as NCT03259958, this PHASE1 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Corium, Inc., it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2018 — Nov 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Sep 2017 — Nov 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Corium, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .